Journal Title：Expert Opinion On Drug Metabolism & Toxicology

Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.

The Editors welcome:

Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug-drug interactions, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data.

Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drug.

The audience consists of scientists and managers in the pharmaceutical industry, pharmacologists, clinical toxicologists and related professionals.

《藥物代謝與毒理學專家意見》（ISSN 1742-5255 [印刷版]，1744-7607 [電子版]）是一本 MEDLINE 索引、同行評審的國際期刊，發(fā)表有關 ADME-Tox 各個方面的評論文章。每篇文章都包含作者自己對未來發(fā)展范圍的專家意見。

歡迎編輯：

評論涵蓋與特定藥物、藥物間相互作用、藥物類別或其在特定人群中的使用有關的代謝、藥代動力學和毒理學問題；與藥物代謝、處置和排泄有關的酶有關的問題；藥物代謝和毒理學研究所涉及的技術；獲取 ADME-Tox 數(shù)據(jù)的新技術。

藥物評估審查特定藥物的臨床、毒理學和藥代動力學數(shù)據(jù)。

聽眾包括制藥行業(yè)的科學家和管理人員、藥理學家、臨床毒理學家和相關專業(yè)人士。

Expert Opinion On Drug Metabolism & Toxicology創(chuàng)刊于2005年，由Taylor and Francis Ltd.出版商出版，收稿方向涵蓋醫(yī)學 - 生化與分子生物學全領域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業(yè)認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 偏慢,4-8周 ，影響因子指數(shù)3.9，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。